Tenax Therapeutics (TENX) Interest Expenses (2010 - 2024)
Tenax Therapeutics recorded quarterly Interest Expenses of -$1000.0 in Q4 2024, down 114.29% quarter-over-quarter from $7000.0 in Q3 2024, and down 145.72% year-over-year from $2187.0 in Q1 2024.
Tenax Therapeutics' Interest Expenses history runs 10 years deep, the most recent figure standing at -$1000.0 for Q4 2024.
- In Q4 2024, Interest Expenses fell 145.72% year-over-year to -$1000.0; the TTM figure through Sep 2025 stood at -$1000.0 (down 103.82% YoY), while the FY2024 annual figure was $23000.0, down 4.17% from the prior year.
- Interest Expenses came in at -$1000.0 for Q4 2024 at Tenax Therapeutics, down from $7000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $9126.0 in Q2 2023 to a low of -$1000.0 in Q4 2024.
- A 5-year average of $3299.6 and a median of $2387.0 in 2022 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses jumped 1334.68% in 2023 and tumbled 145.72% in 2024, its largest moves.
- Tenax Therapeutics' Interest Expenses stood at $2643.0 in 2020, then sank by 87.29% to $336.0 in 2021, then increased by 10.71% to $372.0 in 2022, then surged by 487.9% to $2187.0 in 2023, then sank by 145.72% to -$1000.0 in 2024.
- According to Business Quant data, Interest Expenses over the past three periods registered -$1000.0, $7000.0, and $9000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Dec 31, 2023 | 2,187.00 |
| Dec 31, 2023 | 2,187.00 |
| Sep 30, 2023 | 5,337.00 |
| Sep 30, 2023 | 5,337.00 |
| Jun 30, 2023 | 9,126.00 |
| Jun 30, 2023 | 9,126.00 |
| Mar 31, 2023 | 7,350.00 |
| Mar 31, 2023 | 7,350.00 |
| Sep 30, 2022 | 372.00 |
| Sep 30, 2022 | 372.00 |
| Jun 30, 2022 | 1,484.00 |
| Jun 30, 2022 | 1,484.00 |
| Mar 31, 2022 | 2,587.00 |
| Mar 31, 2022 | 2,587.00 |
| Jun 30, 2021 | 336.00 |
| Jun 30, 2021 | 336.00 |
| Mar 31, 2021 | -613.00 |
| Mar 31, 2021 | -613.00 |
| Dec 31, 2020 | 2,643.00 |
| Dec 31, 2020 | 2,643.00 |
| Sep 30, 2020 | -610.00 |
| Sep 30, 2020 | -610.00 |
| Jun 30, 2020 | -406.00 |
| Jun 30, 2020 | -406.00 |
| Dec 31, 2015 | 1,507.00 |
| Dec 31, 2015 | 1,507.00 |
| Sep 30, 2015 | 571.00 |
| Sep 30, 2015 | 571.00 |
| Jun 30, 2015 | 1,401.00 |
| Jun 30, 2015 | 1,401.00 |
| Apr 30, 2013 | 623,252.00 |
| Apr 30, 2013 | 623,252.00 |
| Jan 31, 2013 | 821,777.00 |
| Jan 31, 2013 | 821,777.00 |
| Oct 31, 2012 | 867,524.00 |
| Oct 31, 2012 | 867,524.00 |
| Jul 31, 2012 | 1.93 Mn |
| Jul 31, 2012 | 1.93 Mn |
| Apr 30, 2012 | 762,500.00 |
| Apr 30, 2012 | 762,500.00 |
| Jan 31, 2012 | 5.34 Mn |
| Jan 31, 2012 | 5.34 Mn |
| Oct 31, 2011 | 871,768.00 |
| Oct 31, 2011 | 871,768.00 |
| Jul 31, 2011 | 435,798.00 |
| Jul 31, 2011 | 435,798.00 |
| Apr 30, 2011 | -121,881.00 |
| Apr 30, 2011 | -121,881.00 |
| Jan 31, 2011 | -43,093.00 |
| Jan 31, 2011 | -43,093.00 |
| Oct 31, 2010 | 5,383.00 |
| Oct 31, 2010 | 5,383.00 |
| Jul 31, 2010 | 1,206.00 |
| Jul 31, 2010 | 1,206.00 |